US biotechnology company Metsera: The revised Pfizer (PFE.N) proposal requires partner companies to issue a statement indicating that "the Novo Nordisk (NVO.N) proposal is too risky and not feasible".
2025-11-04
US biotechnology company Metsera: The revised Pfizer (PFE.N) proposal requires partner companies to issue a statement indicating that "the Novo Nordisk (NVO.N) proposal is too risky and not feasible".